These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33590292)

  • 21. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
    Dudley CV; Baer B; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for manufacturing cell therapy products aligned with patient needs.
    Guha P; Katz SC
    Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells.
    Holzinger A; Abken H
    Pharmacology; 2022; 107(9-10):446-463. PubMed ID: 35696994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
    Date V; Nair S
    Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T-Cells.
    Nair R; Westin J
    Adv Exp Med Biol; 2020; 1244():215-233. PubMed ID: 32301017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group.
    Nezvalova-Henriksen K; Langebrake C; Bauters T; Moreno-Martinez ME; Ahnfelt E; Ekelund H; Domingos V; Pires V; Bonnin A; Bojanić I; Cabrerizo Y; Terwel S; Tam A
    Bone Marrow Transplant; 2023 Oct; 58(10):1069-1074. PubMed ID: 37528237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
    Abou-El-Enein M; Elsallab M; Feldman SA; Fesnak AD; Heslop HE; Marks P; Till BG; Bauer G; Savoldo B
    Blood Cancer Discov; 2021 Sep; 2(5):408-422. PubMed ID: 34568831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T-Cell Therapy: Update on the State of the Science.
    Lamprecht M; Dansereau C
    Clin J Oncol Nurs; 2019 Apr; 23(2):6-12. PubMed ID: 30880819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.
    Pantin J; Battiwalla M
    Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
    Alcantara M; Du Rusquec P; Romano E
    Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.
    Albinger N; Hartmann J; Ullrich E
    Gene Ther; 2021 Sep; 28(9):513-527. PubMed ID: 33753909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
    Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
    Lam C; Meinert E; Yang A; Cui Z
    Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities.
    Kansagra A; Farnia S; Majhail N
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32347759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What will (and should) be improved in CAR immunotherapy?
    González-Navarro EA; Español M; Egri N; Castellà M; Calderón H; España C; Guijarro C; Heredia L; Pascal M; Juan Otero M
    Int Rev Cell Mol Biol; 2022; 370():149-161. PubMed ID: 35798504
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.